The development of Covid-19 vaccines at unprecedented speed during the pandemic required billions of dollars in investment by governments, pharmaceutical companies and research institutions.
The stakes were enormous: Covid-19 claimed more than 7.1 million lives worldwide, including over 5.33 lakh in India, according to officially reported figures. But the investment in vaccines paid off many times over.
A global study covering 173 countries has found that every dollar spent on developing and delivering the vaccines generated an estimated $59.70 to $809 in economic value during the first year of the vaccination programme.
Published in PLOS Medicine, the study "A global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation" found that the health and economic benefits of Covid vaccination far outweighed the investment.
The findings underline how spending on vaccines can deliver returns well beyond preventing illness and deaths by reducing hospital costs, protecting productivity and helping economies remain functional during health emergencies.
The researchers estimated that global spending on vaccine development, manufacturing and delivery stood at $79.4 billion. The resulting health and economic benefits were valued at between $6.43 trillion and $64.3 trillion.
The analysis covered the first year of vaccination, from December 8, 2020, to December 8, 2021, when vaccines had their greatest impact because population immunity was still limited.
Researchers assessed the benefits through several measures, including years of life gained, improved quality of life, productivity preserved and healthcare costs avoided. They used both cost-benefit and cost-effectiveness approaches to estimate the value of lives saved and illness prevented.
The findings reinforce an important public health lesson: preventing disease can be far less costly than treating its complications. By averting severe infections, hospitalisations and deaths, vaccines also reduce the financial burden on families, health systems and economies.
“Our study provides evidence that the unprecedented, rapid investments made into COVID-19 vaccines early in the pandemic paid off massively both in health and economic benefits,” said study author Mark Jit, professor of global health at New York University School of Global Public Health.
Lead author Hallie Benjamin, who worked on the research as a master's student at the London School of Hygiene & Tropical Medicine, said the benefits outweighed the substantial upfront investment within just one year.
However, the economic gains were not distributed equally. High-income countries recorded greater returns because they secured vaccines earlier, achieved higher uptake and rolled them out faster. Their older populations also faced a greater risk of severe disease.
Low- and middle-income countries received widespread access much later, often after large sections of their populations had already contracted the virus and developed some immunity. Yet, even in these countries, the healthcare costs and productivity losses avoided through vaccination were substantial relative to their economies and populations.
Jit said faster and more equitable access to vaccines was essential to ensure that countries facing the greatest health risks could benefit in time.
The researchers cautioned that their analysis covered only the first year of vaccination and did not estimate the economic returns in subsequent years, when infections declined and population immunity increased.
They nevertheless said the returns are measured not only in money saved but also in lives protected, years of healthy life gained and economic activity preserved.
